Skip to main content

Table 1 Patient characteristics

From: Mature results of a randomized trial comparing two fractionation schedules of high dose rate endoluminal brachytherapy for the treatment of endobronchial tumors

  Group I (n = 60) Group II (n = 82)
Median Age (range) 64 (39–86) 65 (40–88)
Male n = 49 (81.7%) n = 53 (67.1%)
Female n = 11 (18.3%) n = 27 (32.9%)
Tumor stage
I 3.5% 2.3%
II 1.8% 0
IIIA 15.8% 15.2%
IIIB 26.3% 16.5%
IV 52.6% 65.8%
Histological features
Squamous Cell Carcinoma 53.4% 40.2%
Adeno Carcinoma 17.2% 26.8%
Large-Cell Carcinoma 8.6% 4.9%
Oat Cell Carcinoma 15.5% 11.0%
Adenoid-cystic Carcinoma 0 2.4%
Other 5.1% 14.6%
Pre-Treatment: (more than 100% because of different treatment combinations)
None 2.6% 12.9%
Surgery 29.4% 20.0%
Brachytherapy 2% 4.2%
Ext. Irradiation 41.2% 35.6%
Chemotherapy 23.7% 27.1%
ND-YAG laser 33.3% 38.8%
Stent 7.9% 9.9%
Combinations 45.2% 45.5%
Proximal localization of the irradiation probe
Trachea 17.9% 20.8%
Right main bronchus 57.1% 55.8%
Left main bronchus 5.4% 7.8%
Right distal bronchus 12.5% 13.9%
Left distal bronchus 7.1% 2.6%